Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial von Dent, S., Cortés, J., Im, Y.-H., Diéras, V., Harbeck, N., Krop, I.E., Wilson, T.R., Cui, N., Schimmoller, F., Hsu, J.Y., He, J., De Laurentiis, M., Sousa, S., Drullinsky, P., Jacot, W.

Volltext

Genomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumours from >165,000 pan-solid tumours von Wilson, T.R., Sokol, E.S., Trabucco, S.E., Newberg, J.Y., Simmons, B., Riehl, T., Maund, S.L.

Volltext

443PD - Genomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumours from >165,000 pan-solid tumours von Wilson, T.R., Sokol, E.S., Trabucco, S.E., Newberg, J.Y., Simmons, B., Riehl, T., Maund, S.L.

Volltext

Prehabilitation in elective abdominal cancer surgery in older patients: systematic review and meta‐analysis von Daniels, S. L., Lee, M. J., George, J., Kerr, K., Moug, S., Wilson, T. R., Brown, S. R., Wyld, L.

Volltext

1193P Clinical validity of FoundationOne liquid CDx (F1L CDx) assay as an aid in selecting patients for treatment with entrectinib von Dziadziuszko, R., André, F., Yip, W.-K., Wu, X., Skoletsky, J., Woodhouse, R., Hung, T., Wilson, T.R., Riehl, T., Dennis, L., Li, M.

Volltext

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer von Diéras, V., Campone, M., Yardley, D.A., Romieu, G., Valero, V., Isakoff, S.J., Koeppen, H., Wilson, T.R., Xiao, Y., Shames, D.S., Mocci, S., Chen, M., Schmid, P.

Volltext

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers von Fumagalli, D., Wilson, T.R., Salgado, R., Lu, X., Yu, J., O'Brien, C., Walter, K., Huw, L.Y., Criscitiello, C., Laios, I., Jose, V., Brown, D.N., Rothé, F., Maetens, M., Zardavas, D., Savas, P., Larsimont, D., Piccart-Gebhart, M.J., Michiels, S., Lackner, M.R., Sotiriou, C., Loi, S.

Volltext

Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2 von Doebele, R.C., Dziadziuszko, R., Drilon, A., Shaw, A., Wolf, J., Farago, A.F., Dennis, L., Riehl, T., Simmons, B., Wu, C., Chang, C.-W., Choeurng, V., Wilson, T.R.

Volltext

LBA28 - Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2 von Doebele, R.C., Dziadziuszko, R., Drilon, A., Shaw, A., Wolf, J., Farago, A.F., Dennis, L., Riehl, T., Simmons, B., Wu, C., Chang, C.-W., Choeurng, V., Wilson, T.R.

Volltext

Chemoresistance in solid tumours von Wilson, T.R., Longley, D.B., Johnston, P.G.

Volltext

3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen... von Jacot, W., Savage, H.M., Dent, S., Cortés, J., Im, Y-H., Dieras, V.C., Harbeck, N., Krop, I.E., Chen, J., Sokol, E., Schimmoller, F., Hsu, J., De Laurentiis, M., Wilson, T.R.

Volltext

Targeted NGS profiling identifies genomic alterations associated with high-risk eBC von Wilson, T.R., Udyavar, A.R., Chang, C-W., Giltnane, J., Spoerke, J.M., Aimi, J., Savage, H., Daemen, A., Bourgon, R., Lackner, M.R.

Volltext

Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy von Ignatiadis, M., Van den Eynden, G., Salgado, R., Fornili, M., Bareche, Y., Desmedt, C., Rothé, F., Maetens, M., David, V., Holgado, E., McNally, V., Kiermaier, A., Savage, H.M., Wilson, T.R., Cortes, J., Schneeweiss, A., Willard-Gallo, K., Biganzoli, E., Sotiriou, C.

Volltext

22 - Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy von Ignatiadis, M., Van den Eynden, G., Salgado, R., Fornili, M., Bareche, Y., Desmedt, C., Rothé, F., Maetens, M., David, V., Holgado, E., McNally, V., Kiermaier, A., Savage, H.M., Wilson, T.R., Cortes, J., Schneeweiss, A., Willard-Gallo, K., Biganzoli, E., Sotiriou, C.

Volltext

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer von Arthur, L. M., Turnbull, A. K., Renshaw, L., Keys, J., Thomas, J. S., Wilson, T. R., Lackner, M. R., Sims, A. H., Dixon, J. M.

Volltext

Australian funnel-web spiders evolved human-lethal δ-hexatoxins for defense against vertebrate predators von Herzig, Volker, Sunagar, Kartik, Wilson, David T. R., Pineda, Sandy S., Israel, Mathilde R., Dutertre, Sebastien, McFarland, Brianna Sollod, Undheim, Eivind A. B., Hodgson, Wayne C., Alewood, Paul F., Lewis, Richard J., Bosmans, Frank, Vetter, Irina, King, Glenn F., Fry, Bryan G.

Volltext

SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally a... von Baselga, J., Cortes Castan, J., De Laurentiis, M., Dieras, V., Harbeck, N., Hsu, J., Jin, H., Schimmoller, F., Wilson, T.R., Im, Y.-H., Jacot, W., Krop, I.E., Verma, S.

Volltext

Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) w... von Saura, C., de Azambuja, E., Hlauschek, D., Oliveira, M., Zardavas, D., Jallitsch-Halper, A., de la Pena, L., Nuciforo, P., Ballestrero, A., Fornier, M.N., Boer, K., Ciruelos, E., Valero, V., Wilson, T.R., Stout, T.J., Hsu, J.Y., Shi, Y., Piccart, M., Gnant, M., Baselga, J.

Volltext

Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells von Wilson, T R, McEwan, M, McLaughlin, K, Le Clorennec, C, Allen, W L, Fennell, D A, Johnston, P G, Longley, D B

Volltext

Process and outcome differences in the care of patients undergoing elective and emergency right hemicolectomy von Banks, J, Rashid, A, Wilson, T.R, Challand, C.P, Lee, M.J

Volltext bestellen